Imagenetix says 1-TDC complex may prevent oral disease, sepsis, inflammation

By Elaine Rigoli

Tampa, Fla., May 8 - Imagenetix announced the successful completion of in-vitro studies demonstrating the inhibitory function of its pharma compound, 1-tetradecanol complex (1-TDC).

According to a company news release, the main findings include:

• 1-TDC significantly inhibited the growth of Actinomyces viscosus, a microbe that has been shown to play a major role in oral microbial ecosystems. Actinomyces viscosus has been shown to be associated with periodontal disease and other inflammatory diseases.

• 1-TDC significantly inhibited the growth of Staphylococcus aureus, a microbe associated with opportunistic infections leading to sepsis. This finding is important due to the outbreak of the numerous methacillin-resistant Staphylococcus aureus infections around the world. This is also important as atherosclerosis and sepsis share many pathophysiological similarities which are involved in immune function and systemic inflammation;

• 1-TDC significantly inhibited thromboxane A2 production in human recombinant cells. The reduction in thromboxane A2 synthase activity was confirmed in a separate study in which thromboxane synthase receptor inhibition was evident after exposure to 1-TDC. These data demonstrate that this proprietary complex plays a vital role in the regulation of thromboxane A2 production from aracidonic acid metabolism at the cell membrane.

"The significant findings from these studies form the basis for our patent filing on the treatment of inflammatory conditions including periodontal and cardiovascular diseases," director of research and development Robert Hesslink said in the release.

"We anticipate further developments in this area over the next 12 to 18 months."

San Diego-based Imagenetix develops treatments for inflammatory diseases, including over-the-counter topical creams and skin-care products for inflammation-related markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.